Wuchereria bancrofti recombinant antigen-derived poly- and monoclonal antibodies for the detection of circulating antigen(s) in the sera of lymphatic filarial patients

1996 ◽  
Vol 70 (1) ◽  
pp. 69-74 ◽  
Author(s):  
J.G. Theodore ◽  
P. Kaliraj
Keyword(s):  
Monoclonal Antibodies ◽  
Membrane Filtration ◽  
Wuchereria Bancrofti ◽  
Recombinant Antigen ◽  
Parasite Antigen ◽  
Filarial Antigen ◽  
Finger Prick ◽  
Circulating Antigen ◽  
Antibody Elisa

AbstractA sandwich antibody ELISA was employed for the detection of circulating filarial antigen in patients with bancroftian filariasis. Wuchereria bancrofti recombinant antigen-derived polyclonal and monoclonal antibodies were successfully used as the revealing antibodies and their efficiency was compared. All the microfilariae (mf) positive (by finger prick and examination of 20 μl of blood under the microscope) individuals tested showed the presence of circulating antigen(s). Among the antigen positive endemic normals (mf negative by the finger prick method), 43% showed microfilariae by a sensitive parasitological method viz. membrane filtration of the night blood samples. A significant correlation was observed between the parasite antigen levels and the blood microfilaria counts among the mf carriers. This information on the parasite antigen levels could be an ideal monitor to indicate the degree of active infection and in the follow up of chemotherapy.

scholarly journals An open label, randomized clinical trial to compare the tolerability and efficacy of ivermectin plus diethylcarbamazine and albendazole vs. diethylcarbamazine plus albendazole for treatment of brugian filariasis in Indonesia

2021 ◽  
Vol 15 (3) ◽  
pp. e0009294
Author(s):  
Taniawati Supali ◽  
Yenny Djuardi ◽  
Michael Christian ◽  
Elisa Iskandar ◽  
Rahmat Alfian ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Drug Combination ◽  
Membrane Filtration ◽  
Wuchereria Bancrofti ◽  
Open Label ◽  
Safety And Efficacy ◽  
Treatment Groups ◽  
Administration Regimen ◽  
Filarial Antigen ◽  
One Year

Improved treatments for lymphatic filariasis (LF) could accelerate the global elimination program for this disease. A triple drug combination of the anti-filarial drugs ivermectin, diethylcarbamazine (DEC) and albendazole (IDA) has been shown to be safe and effective for achieving sustained clearance of microfilariae (Mf) of the filarial parasite Wuchereria bancrofti from human blood. However, the triple drug combination has not been previously been evaluated for treatment of brugian filariasis, which accounts for about 10% of the global LF burden. This hospital-based clinical trial compared the safety and efficacy of IDA with that of the standard treatment (DEC plus albendazole, DA) in persons with Brugia timori infections on Sumba island, Indonesia. Fifty-five asymptomatic persons with B. timori Mf were treated with either a single oral dose of IDA (28 subjects) or with DEC plus albendazole (DA, 27 subjects). Participants were actively monitored for adverse events (AE) for two days after treatment by nurses and physicians who were masked regarding treatment assignments. Passive monitoring was performed by clinical teams that visited participant’s home villages for an additional five days. Microfilaremia was assessed by membrane filtration of 1 ml night blood at baseline, at 24h and one year after treatment. IDA was more effective than DA for completely clearing Mf at 24 hours (25/28, 89% vs. 11/27, 41%, P < 0.001). By 12 months after treatment, only one of 28 IDA recipients had Mf in their blood (4%) vs. 10 of 27 (37%) in persons treated with DA (P = 0.002). Approximately 90% of participants had antibodies to recombinant filarial antigen BmR1 at baseline. Antibody prevalence decreased to approximately 30% in both treatment groups at 12 months. About 45% of persons in both treatment groups experienced AE such as fever, muscle aches, lower back, joint and abdominal pain. These were mostly mild and most common during the first two days after treatment. No participant experienced a severe or serious AE. This study showed that IDA was well-tolerated and significantly more effective for clearing B. timori Mf from the blood than DA. Larger studies should be performed to further assess the safety and efficacy of IDA as a mass drug administration regimen to eliminate brugian filariasis. Trial Registration: NCT02899936.

scholarly journals Bancroftian Filariasis Still Endemic in Some Foci in Sohag Governorate, Upper Egypt

2019 ◽  
Vol 1 (1) ◽  
pp. 1-7
Author(s):  
Refaat MA Khalifa ◽  
Amal M Ahmed ◽  
Mohamed AA Taha ◽  
Nasr Eldeen MM Ali ◽  
Haitham KA Abd El Samea
Keyword(s):  
Lower Limb ◽  
Large Scale ◽  
Wuchereria Bancrofti ◽  
Endemic Country ◽  
Chronic Case ◽  
Bancroftian Filariasis ◽  
Upper Egypt ◽  
The World ◽  
Finger Prick

Bancroftian filariasis (BF) is a debilitating disease that has plagued Egypt since the time of the pharaohs. Egypt is the first large endemic country in the world to reach the five-year mark in its national campaign. Now that the mass treatments are completed, a follow-up epidemiological assessment will reveal whether this large-scale, pioneering campaign has been successful in finally eliminating the disease. Hence the aim of the present work was to detect the prevalence of bancoftian filariasis in Tema, El-Maragha, Akhmeem and Girga districts in Sohag Governorate, Upper Egypt. Finger prick thick blood films were randomly collected from 500 clinically suspected individuals representing different sexes and ages suffering from lower limb non-pitting edema and/or inguinal lymphadenitis from May 2015 to February 2017. Three patients (0.6%) were infected with microfilariae of Wuchereria bancrofti while one chronic case was detected with severe chronic elephantiasis that was amicrofilaraemic but was confirmed serologically. Results were discussed in regards of age, gender, occupation, locality and residence. It was concluded that bancroftian filariasis is still endemic in three districts (Tema, El- maragha and Girga). Although in sporadic few cases, the problem should be taken seriously as one microfilaramic patient could be a patent reservoir for spreading of the disease through infecting the prevailing Culex pipiense mosquito intermediate host.

Parasite antigenaemia and IgG4antibodies to a filarial protease in an endemic human population in India

2003 ◽  
Vol 77 (4) ◽  
pp. 287-290
Author(s):  
M.S. Bal ◽  
M.K. Beuria ◽  
N.N. Mandal ◽  
M.K. Das
Keyword(s):  
Risk Factor ◽  
Human Population ◽  
Wuchereria Bancrofti ◽  
Filarial Antigen ◽  
Circulating Filarial Antigen

AbstractLevels of circulating filarial antigen (Og4C3) and IgG4antibodies to a filarial protease were determined in subjects ofWuchereria bancroftiexposed sera from Orissa, India. In addition to all individuals with antigenaemia (microfilaraemia), IgG4antibodies were also detected in some individuals without antigenaemia. A 2-year longitudinal follow-up indicated that IgG4seropositivity in asymptomatic amicrofilaraemics could be a risk factor for acquiring infection (antigenaemia).

scholarly journals Detection of Paracoccidioides brasiliensis gp70 Circulating Antigen and Follow-Up of Patients Undergoing Antimycotic Therapy

2004 ◽  
Vol 42 (10) ◽  
pp. 4480-4486 ◽  
Author(s):  
S. H. Marques da Silva ◽  
D. de Mattos Grosso ◽  
J. D. Lopes ◽  
A. L. Colombo ◽  
M. H. S. L. Blotta ◽  
...  
Keyword(s):  
Paracoccidioides Brasiliensis ◽  
Antimycotic Therapy ◽  
Circulating Antigen

EVALUATION OF LYMPHATIC FILARIASIS AFTER TWO ROUNDS OF MASS DRUG ADMINISTRATION IN LAU LOCAL GOVERNMENT AREA OF TARABA STATE NIGERIA

2021 ◽  
Vol 4 (4) ◽  
pp. 513-519
Author(s):  
D. E. Akafyi ◽  
I. S. Ndams ◽  
S. A. Luka ◽  
F. S. Ojeleye ◽  
S. O. Elkanah ◽  
...  
Keyword(s):  
Local Government ◽  
Drug Administration ◽  
Mass Drug Administration ◽  
Clinical Manifestations ◽  
Wuchereria Bancrofti ◽  
Local Government Area ◽  
Filarial Antigen ◽  
Physical Examinations ◽  
The Impact ◽  
Card Test

This study was undertaken to evaluate the effects of Mass Drug Administration (MDA) on Wuchereria bancrofti (microfilariae) after two rounds of combined Ivermectin and Albendazole distribution. A total of 221 participants were recruited in three communities in Lau Local Government Area of Taraba State by convenience sampling method. Questionnaires and physical examinations were used to assess clinical manifestations associated with the infection. Blood samples were collected by finger prick method and stained with Giemsa stain for examination to establish the presence of W. bancrofti while immunochromatographic card test was performed to determine the presence of filarial antigen in serum. Previous data were used to determine the pre-drug prevalence of the parasite. The results showed that the drug did not significantly reduce the clinical manifestations reported among the patients. The microfilariae prevalence and microfilaria mean density after two rounds of drug administration was 19.5% and 1.49%, while the pre- MDA prevalence and microfilaria mean density was 27.8% and 2.44% respectively. There was a statistically significant decrease of microfilaria prevalence (P<0.05) after two rounds of MDA. There was no significant effect of MDA by age, sex and occupation-related microfilariae prevalence in the study area.  In conclusion, the study reveals that microfilaria prevalence and load decreased after two rounds of MDA of combined Ivermectin and Albendazole distribution amongst the studied populations. Routine evaluation of the MDA is required to assess the impact of the drug for the eventual elimination of the infection.

Anti-CEA and Other Antibodies in the Study of Gastrointestinal Tumors

1992 ◽  
Vol 7 (3) ◽  
pp. 198-202 ◽  
Author(s):  
S. Lastoria ◽  
C. Caracò ◽  
E. Vergara ◽  
L. Castelli ◽  
M. Salvatore
Keyword(s):  
Monoclonal Antibodies ◽  
Distant Metastases ◽  
Gastrointestinal Tumors ◽  
Primary Tumors ◽  
Factors Affecting ◽  
Normal Tissues ◽  
Antibody Uptake ◽  
The Impact

Localization of gastrointestinal tumors by means of labeled monoclonal antibodies is a new, sensitive and suitable technique currently used in several centers. Encouraging results have been documented with several monoclonal antibodies by different authors. This article reviews our experience with radioimmunoscintigraphy in 59 patients with colorectal cancer in follow-up, using 131I and 111In labeled B72.3, and in 16 patients with primary gastrointestinal tumors using 99mTc anti-CEA monoclonal antibody (type F023C5). The sensitivity of both B72.3 and anti-CEA was greater than 70% either for primary tumors and abdominal recurrences or distant metastases except hepatic ones. A significant gradient in antibody uptake was measured on surgical biopsies between tumors and normal tissues allowing a good in vivo contrast for gamma detection. We have defined the impact of some factors affecting in vivo tumor targeting. In fact, pharmacodynamics of MAbs, percentage of injected dose bound to tissues were measured, and in particular antigenic content in tumor nodules was quantified. Furthermore, the results of RIS were compared to those obtained by CT and other imaging modalities.

Standardization, specificity, and diagnostic sensitivity of four immunoassays for carcinoembryonic antigen

1991 ◽  
Vol 37 (2) ◽  
pp. 231-236 ◽  
Author(s):  
Ole P Börmer
Keyword(s):  
Colorectal Cancer ◽  
Monoclonal Antibodies ◽  
Carcinoembryonic Antigen ◽  
Normal Values ◽  
The Other ◽  
Reference Limit ◽  
Sandwich Type ◽  
Reference Preparation ◽  
Colorectal Cancer Patients

Abstract Four "sandwich"-type immunoassays for carcinoembryonic antigen (CEA) based on monoclonal antibodies (Abbott CEA-RIA Monoclonal, Pharmacia/Wallac Delfia CEA kit, Roche CEA EIA Duomab 60, and our in-house immunoradiometric assay) were compared for 357 samples from colorectal cancer patients and samples from 48 patients with chronic liver disease or with acute, irrelevant diseases. Relative to a common 5 micrograms/L reference limit, all four assays agreed regarding classification in 92% to 94% of the samples in the colorectal cancer samples, with the Abbott and Roche assays giving slightly more "normal" values. Cross-testing of CEA standards and the 1st International Reference Preparation 73/601 showed that calibration differences could not be eliminated by the use of a common standard. It has been earlier demonstrated that the monoclonal antibodies in the Roche assay have an epitope group specificity slightly different from those of the other three assays. This can explain why the correlations involving the Roche assay were weaker (r = 0.84-0.87) than those obtained with the other assays (r = 0.94-0.97). I conclude that agreement between the assays studied is as good as can be expected when different antibodies are used; nevertheless, consistent discrepancies between assays in several patients still necessitate the use of the same assay during follow-up.

Sign in / Sign up

Export Citation Format

Share Document